form8kreemadecisions.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): January 21, 2011
 
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware
 
000-50513
 
13-3831168
(State or other jurisdiction
 
(Commission
 
(I.R.S. Employer
of incorporation)
 
File Number)
 
Identification No.)
         
   
15 Skyline Drive, Hawthorne, NY
 
10532
   
(Address of principal executive offices)
 
(Zip Code)
         
Registrant’s telephone number, including area code:  (914) 347-4300

Not Applicable
Former name or former address, if changed since last report
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 
 

 

Item 8.01 Other Events

    On January 21, 2011, Acorda Therapeutics, Inc. issued a Statement, posted in the “Investors” and “News & Events” sections of its corporate website (www.acorda.com), regarding the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) decision against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS).  FAMPYRA is the proposed trade name in Europe for the product commercialized in the U.S. by Acorda Therapeutics under the trade name Ampyra® (dalfampridine) Extended Release Tablets, 10 mg.  A copy of the Statement is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.

 
 

 


Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.                    Description

99.1                                Statement dated January 21, 2011

 
 

 

SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Acorda Therapeutics, Inc.
     
January 21, 2011
By:
/s/ David Lawrence
   
Name: David Lawrence
   
Title: Chief Financial Officer

 
 

 

Exhibit Index



Exhibit No.                                                                         Description


99.1                                                                                     Statement dated January 21, 2011